V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 23.4 NOK
Market Cap: 1B NOK
Have any thoughts about
Vistin Pharma ASA?
Write Note

Vistin Pharma ASA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vistin Pharma ASA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
V
Vistin Pharma ASA
OSE:VISTN
Revenue
kr423.6m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Photocure ASA
OSE:PHO
Revenue
kr526.3m
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
15%
N
Navamedic ASA
OSE:NAVA
Revenue
kr543.5m
CAGR 3-Years
32%
CAGR 5-Years
24%
CAGR 10-Years
12%
S
SoftOx Solutions AS
OSE:SOFTX
Revenue
kr13.3m
CAGR 3-Years
29%
CAGR 5-Years
20%
CAGR 10-Years
N/A
No Stocks Found

Vistin Pharma ASA
Glance View

Market Cap
1B NOK
Industry
Pharmaceuticals

Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.

VISTN Intrinsic Value
22.56 NOK
Overvaluation 4%
Intrinsic Value
Price
V

See Also

What is Vistin Pharma ASA's Revenue?
Revenue
423.6m NOK

Based on the financial report for Sep 30, 2024, Vistin Pharma ASA's Revenue amounts to 423.6m NOK.

What is Vistin Pharma ASA's Revenue growth rate?
Revenue CAGR 5Y
15%

Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Vistin Pharma ASA have been 17% over the past three years , 15% over the past five years .

Back to Top